Moderna, Inc.
MRNA is being valued like a successful oncology platform already exists, while the current business still has $1.9B revenue, -118.0% operating margin, and a 27.38x sales multiple on a shrinking commercial base.
The stock is being priced for a strategic future that has not been commercialized yet. At $61.1B market cap, investors are underwriting far more than the current business, which posted $1.9B of FY2025 revenue, EPS of -$7.26, -118.0% operating margin, and -106.3% net margin. That can work if oncology and respiratory pipeline assets convert quickly into revenue and margin, but management's own FY26 outlook is still only up to 10% revenue growth, with no FY26 revenue assumed from mFLUSIVA or mCOMBRIAX.
The bullish argument is understandable. Moderna still has a strong platform, a solid balance sheet, and better cost control than it had two years ago. The current 2026 framework of $4.7B GAAP opex ex litigation and $4.0B cash costs is materially better than the 2024 Q3 call's $5.0B 2026 cash-cost target. The company also continues to beat quarterly EPS expectations, and mNEXSPIKE's 24% U.S. retail COVID share shows that the franchise is not dead. If cancer vaccine data continue to improve and flu is approved, the equity can stay expensive for longer than fundamentals alone would suggest.
The problem is that the market has already paid for much of that hope. Shares are 159.39% higher in 3 months, 186.4% above the 200-day average, and sit 1.1% below the 52-week high. That is not a setup where investors are getting paid for obvious uncertainty. The commercial base is still tied heavily to seasonal respiratory demand, management still assumes a decline in U.S. COVID vaccination rates, and norovirus just failed an interim early-success hurdle. Meanwhile, valuation is extreme at 27.38x sales against a 7.7x peer average.
The case depends on three things. First, cost discipline must keep improving so the company reaches cash break-even credibility. Second, flu and combo programs must become real revenue lines, not perpetual next-year stories. Third, oncology must mature from a sentiment driver into a product with visible economics. Until those three are more tangible, the stock price looks ahead of the business rather than merely ahead of consensus.
Flu approval, sustained oncology enthusiasm, and proof that the commercial platform extends beyond COVID keep sentiment elevated despite current losses.
Cost cuts continue and cash runway stays intact, but only modest growth materializes and valuation compresses toward the engine's sales_quality_blend target.
COVID demand falls faster than expected, flu contributes nothing, and the market stops paying 27.38x sales for a business still posting triple-digit negative operating margins.
Quant call (SELL) diverges from analyst consensus (Hold: 3 buy / 8 hold / 3 sell) — resolve explicitly.
In the short run, the market is a voting machine, but in the long run, it is a weighing machine.
Forward earnings power is still weak because FY26 guidance only points to up to 10% revenue growth while total GAAP operating expenses ex litigation are still $4.7B, leaving the stock impossible to underwrite on a normal forward P/E basis despite the market cap at $61.1B. The moat today is still mostly platform speed, manufacturing know-how, and regulatory experience in mRNA, but 3 to 5 years out it is less secure if oncology and combo vaccines do not convert into commercial products at scale. AI is a real advantage in target selection and personalized cancer vaccine design, and recent cancer-vaccine headlines explain sentiment, but AI does not erase the need for large trials, reimbursement, and manufacturing economics. Regulation and demand also cut both ways, because flu could add TAM if approved, yet management itself assumes no FY26 revenue from mFLUSIVA or mCOMBRIAX and a lower U.S. COVID vaccination rate.
- Valuation is stretched at 27.38x P/S versus a peer average of 7.7x, despite FY2025 revenue declining 37.5%.
- Profitability remains deeply negative with -118.0% operating margin, -106.3% net margin, and Q2 2026 EBITDA of -$0.70B on $145M revenue.
- Price action has outrun fundamentals, with shares 186.4% above the 200-day average and 159.39% up in 3 months, while the quant base target is $107.73, or -38.3% from current.
- Management reiterated up to 10% FY26 revenue growth and cut both GAAP opex ex litigation and cash cost guidance by $0.2B, to $4.7B and $4.0B respectively.
- Balance sheet remains a real cushion, with $6.9B cash and investments at Q2 and expected $4.7B-$5.2B year-end cash and investments even after a $950M litigation payment in Q3.
- Commercial execution in COVID improved with mNEXSPIKE capturing 24% of the U.S. retail COVID market in its first season.
- Recent earnings execution has been better than feared, with 8 straight EPS beats, including +72.7%, +28.8%, and +23.6% versus consensus in the last seven reported quarters.
- The core business is still shrinking, with FY2025 revenue of $1.9B, down 37.5% YoY, and management still assumes a decline in U.S. COVID vaccination rates in FY26.
- The market is paying a premium multiple for a money-losing company, at 27.38x sales and 9.02x book, while peers average just 7.7x sales and profitable biotech peers trade at 15.84x to 31.95x earnings.
- Pipeline execution is mixed: mRNA-1403 norovirus Phase III did not meet the statistical criteria for early success at interim and now requires an added cohort.
- Operating leverage is still poor, with Q2 2026 EBITDA margin of -485.5% and FY26 cost of sales still guided at $1.7B against only up to 10% annual revenue growth.
| Metric | Value | Context |
|---|---|---|
| Current price | $174.72 | Reference price for valuation and scenario framing |
| Quant price target | $107.73 | -38.3% vs current, Low confidence, basis: sales_quality_blend |
| FY2025 revenue | $1.9B | -37.5% YoY |
| FY2025 EPS | -$7.26 | -43.2% YoY |
| Operating margin | -118.0% | Prior FY was -123.3%, still deeply negative |
| Net margin | -106.3% | Losses still exceed revenue base |
| P/S | 27.38x | Vs peer average 7.7x |
| Market cap | $61.1B | Large-cap valuation despite negative earnings |
| Balance sheet | Debt/Equity 0.19, Current ratio 2.29, Total debt $1.3B | Healthy liquidity and modest leverage |
| FCF | -$0.6B | No buybacks, no dividend, capital preserved for operations |
| FY2026 guidance | Revenue growth up to 10%, Cost of sales $1.7B, R&D $2.9B, GAAP opex ex litigation $4.7B, cash costs $4.0B | Guidance reiterated and cost framework lowered by $0.2B |
| 52-week position | $22.28-$176.75 range, now -1.1% vs high | Price is 186.4% above 200-day average after a 159.39% 3-month move |
The biggest risk to a bearish call is that oncology optimism overwhelms near-term fundamentals, especially after the stock already rose 159.39% in 3 months and options positioning is in a positive gamma regime.
The next catalyst is November 5, 2026 earnings, which will test whether management can support the up to 10% FY26 revenue growth outlook after the Q3 litigation cash hit and ahead of any meaningful new product revenue.
Ownership is concentrated in large institutions, with the top holders including Fidelity, BlackRock, Vanguard, Capital World Investors, and Baillie Gifford, and the top-3 institutions controlling 75.1%. Short interest is elevated at 10.51% of float, or 39.2M shares, but it fell 25.9% and days-to-cover is only 2.9, which reduces classic squeeze pressure. Options positioning is in a positive gamma regime, which can damp volatility mechanically, but after a 137% month and a price near the high, positioning looks more supportive of trend persistence than fundamental validation.
Business still appears dominated by respiratory vaccines, with Q2 2026 revenue of $145M helped by strategic partnership sales and COVID still the key commercial driver.
mNEXSPIKE captured 24% of U.S. retail COVID market in its first season, but management still assumes lower U.S. vaccination rates in FY26.
mRESVIA previously underperformed and management assumes no FY26 revenue from mFLUSIVA or mCOMBRIAX despite an August 5 flu PDUFA.
Historical call showed a split between U.S. and international respiratory sales, but current geographic revenue detail is not provided here.
Moderna reiterated up to 10% revenue growth and lowered 2026 cost guidance, but pipeline execution remains mixed.
Execution has improved on costs and quarterly delivery, but product timelines remain mixed. On the positive side, management said in 2024 Q3, "Through efficiency program, we're reducing cash cost to an estimated $5.5 billion in 2025 and $5 billion in 2026," and the current 2026 Q2 framework is better than that, at $4.0B cash costs and $4.7B GAAP opex ex litigation, improved by $0.2B in both categories from prior guidance. Management also said in 2024, "We will continue to adjust our cost structure to ensure we break even on a cash cost basis no later than 2028," and that objective is more credible now given the lower cost base and expected $4.7B-$5.2B year-end cash and investments. But pipeline delivery has been uneven: 2024 highlighted multiple filings and upside from approvals, while 2026 still assumes no FY26 revenue from mFLUSIVA or mCOMBRIAX, and norovirus "did not meet the statistical criteria for early success at its interim analysis." Quarterly EPS execution has clearly beaten the Street, with 8 straight beats, but those beats have not yet translated into durable revenue growth or profitability.
Overall, we are pleased with our first half performance and are reiterating our expectation for revenue growth of up to 10% in 2026.
In aggregate, excluding the $0.9 billion litigation charge, we are expecting total GAAP operating expenses of $4.7 billion and $4 billion of cash costs, which excludes stock-based compensation, depreciation and amortization.
We generated revenue of $0.1 billion, which exceeded the top of our range.
For our norovirus vaccine, mRNA-1403, the Phase III study did not meet the statistical criteria for early success at its interim analysis.
Looking at the second half of the year, on the commercial and financial side, we remain on track for up to 10% revenue growth this year and also remain committed to improving our operational efficiency and achieving our new lowered cash cost guidance of approximately $4 billion.
The moat is real but narrower than the stock price implies. Moderna still has strong mRNA design capability, manufacturing scale, regulatory experience, and enough scientific depth to earn an Innovation Investment score of 100, which matters in fast-cycle vaccine development and personalized oncology. The durability question is commercial, not scientific: if the platform does not generate multiple profitable products beyond COVID over the next 3 to 5 years, the current moat will look more like a good R&D engine than a high-return franchise.
Capital allocation has shifted from expansion to runway protection. The company generated FCF of -$0.6B, has no buybacks and no dividend, and is prioritizing cost reduction, with FY26 cash costs cut to $4.0B from the prior framework. That is the right posture, but discipline is still judged by whether cash burn keeps falling after the $950M litigation settlement and whether late-stage pipeline spending starts to produce revenue rather than just optionality.
MRNA rates a SELL at Low conviction. The business has real scientific assets and enough cash to keep building them, but the stock already reflects a much better commercial outcome than current numbers support. At 27.38x sales with -118.0% operating margin and only up to 10% FY26 revenue growth guided, the burden of proof is on the bull case. A more positive stance would require evidence that new products can lift revenue materially above the current trajectory, or that oncology progress turns into visible earnings power rather than momentum-driven sentiment.
≣ Full research note tap to expand
Executive Summary
SELL, Low conviction. Rated SELL, Low conviction. The stock has moved 159.39% in 3 months and now sits 1.1% below its 52-week high, but the underlying business still shows FY2025 revenue down 37.5% YoY to $1.9B, EPS of -$7.26, and a valuation of 27.38x sales versus 7.7x peers. The near-term setup is dominated by enthusiasm around the cancer vaccine and flu optionality, while management is still guiding only up to 10% revenue growth in 2026 and no FY26 revenue from flu products.
Investment Thesis
The stock is being priced for a strategic future that has not been commercialized yet. At $61.1B market cap, investors are underwriting far more than the current business, which posted $1.9B of FY2025 revenue, EPS of -$7.26, -118.0% operating margin, and -106.3% net margin. That can work if oncology and respiratory pipeline assets convert quickly into revenue and margin, but management's own FY26 outlook is still only up to 10% revenue growth, with no FY26 revenue assumed from mFLUSIVA or mCOMBRIAX.
The bullish argument is understandable. Moderna still has a strong platform, a solid balance sheet, and better cost control than it had two years ago. The current 2026 framework of $4.7B GAAP opex ex litigation and $4.0B cash costs is materially better than the 2024 Q3 call's $5.0B 2026 cash-cost target. The company also continues to beat quarterly EPS expectations, and mNEXSPIKE's 24% U.S. retail COVID share shows that the franchise is not dead. If cancer vaccine data continue to improve and flu is approved, the equity can stay expensive for longer than fundamentals alone would suggest.
The problem is that the market has already paid for much of that hope. Shares are 159.39% higher in 3 months, 186.4% above the 200-day average, and sit 1.1% below the 52-week high. That is not a setup where investors are getting paid for obvious uncertainty. The commercial base is still tied heavily to seasonal respiratory demand, management still assumes a decline in U.S. COVID vaccination rates, and norovirus just failed an interim early-success hurdle. Meanwhile, valuation is extreme at 27.38x sales against a 7.7x peer average.
The case depends on three things. First, cost discipline must keep improving so the company reaches cash break-even credibility. Second, flu and combo programs must become real revenue lines, not perpetual next-year stories. Third, oncology must mature from a sentiment driver into a product with visible economics. Until those three are more tangible, the stock price looks ahead of the business rather than merely ahead of consensus.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Current price | $174.72 | Reference price for valuation and scenario framing |
| Quant price target | $107.73 | -38.3% vs current, Low confidence, basis: sales_quality_blend |
| FY2025 revenue | $1.9B | -37.5% YoY |
| FY2025 EPS | -$7.26 | -43.2% YoY |
| Operating margin | -118.0% | Prior FY was -123.3%, still deeply negative |
| Net margin | -106.3% | Losses still exceed revenue base |
| P/S | 27.38x | Vs peer average 7.7x |
| Market cap | $61.1B | Large-cap valuation despite negative earnings |
| Balance sheet | Debt/Equity 0.19, Current ratio 2.29, Total debt $1.3B | Healthy liquidity and modest leverage |
| FCF | -$0.6B | No buybacks, no dividend, capital preserved for operations |
| FY2026 guidance | Revenue growth up to 10%, Cost of sales $1.7B, R&D $2.9B, GAAP opex ex litigation $4.7B, cash costs $4.0B | Guidance reiterated and cost framework lowered by $0.2B |
| 52-week position | $22.28-$176.75 range, now -1.1% vs high | Price is 186.4% above 200-day average after a 159.39% 3-month move |
Financial Strength
The balance sheet is the core reason this is not a high-conviction short. Leverage is modest at 0.19 debt/equity, the current ratio is 2.29, and management still expects $4.7B-$5.2B of year-end cash and investments after a $950M litigation payment, which buys time for the pipeline. But financial strength does not equal earning power. With FCF at -$0.6B, triple-digit negative operating margins, and FY26 costs still measured in the billions against a sub-$2B FY2025 revenue base, Moderna remains solvent and strategic, not yet financially proven as a multi-product commercial biotech.
Competitive Position
The moat is real but narrower than the stock price implies. Moderna still has strong mRNA design capability, manufacturing scale, regulatory experience, and enough scientific depth to earn an Innovation Investment score of 100, which matters in fast-cycle vaccine development and personalized oncology. The durability question is commercial, not scientific: if the platform does not generate multiple profitable products beyond COVID over the next 3 to 5 years, the current moat will look more like a good R&D engine than a high-return franchise.
Management & Guidance
Guidance is cautiously credible on costs and only moderately credible on growth. Management reiterated, "Overall, we are pleased with our first half performance and are reiterating our expectation for revenue growth of up to 10% in 2026," while also lowering the 2026 cost framework to $4.7B GAAP opex ex litigation and $4.0B cash costs. That conservatism is reinforced by assuming no FY26 revenue from mFLUSIVA or mCOMBRIAX, even with a flu PDUFA on August 5, which reduces the odds of another overpromise. The issue is that management is also still baking in lower U.S. COVID vaccination rates, and recent pipeline news on norovirus shows that execution remains uneven even as cost control improves.
Segment Analysis
- Product revenue (Not disclosed in the provided data): Business still appears dominated by respiratory vaccines, with Q2 2026 revenue of $145M helped by strategic partnership sales and COVID still the key commercial driver.
- COVID franchise (Primary commercial contributor, exact FY2025 share not provided): mNEXSPIKE captured 24% of U.S. retail COVID market in its first season, but management still assumes lower U.S. vaccination rates in FY26.
- RSV / Flu / Combo pipeline (Minimal current revenue contribution): mRESVIA previously underperformed and management assumes no FY26 revenue from mFLUSIVA or mCOMBRIAX despite an August 5 flu PDUFA.
- Geography (Not disclosed in the provided data): Historical call showed a split between U.S. and international respiratory sales, but current geographic revenue detail is not provided here.
Capital Allocation
Capital allocation has shifted from expansion to runway protection. The company generated FCF of -$0.6B, has no buybacks and no dividend, and is prioritizing cost reduction, with FY26 cash costs cut to $4.0B from the prior framework. That is the right posture, but discipline is still judged by whether cash burn keeps falling after the $950M litigation settlement and whether late-stage pipeline spending starts to produce revenue rather than just optionality.
Management Execution & Track Record
Execution has improved on costs and quarterly delivery, but product timelines remain mixed. On the positive side, management said in 2024 Q3, "Through efficiency program, we're reducing cash cost to an estimated $5.5 billion in 2025 and $5 billion in 2026," and the current 2026 Q2 framework is better than that, at $4.0B cash costs and $4.7B GAAP opex ex litigation, improved by $0.2B in both categories from prior guidance. Management also said in 2024, "We will continue to adjust our cost structure to ensure we break even on a cash cost basis no later than 2028," and that objective is more credible now given the lower cost base and expected $4.7B-$5.2B year-end cash and investments. But pipeline delivery has been uneven: 2024 highlighted multiple filings and upside from approvals, while 2026 still assumes no FY26 revenue from mFLUSIVA or mCOMBRIAX, and norovirus "did not meet the statistical criteria for early success at its interim analysis." Quarterly EPS execution has clearly beaten the Street, with 8 straight beats, but those beats have not yet translated into durable revenue growth or profitability.
Positioning & Flows
Ownership is concentrated in large institutions, with the top holders including Fidelity, BlackRock, Vanguard, Capital World Investors, and Baillie Gifford, and the top-3 institutions controlling 75.1%. Short interest is elevated at 10.51% of float, or 39.2M shares, but it fell 25.9% and days-to-cover is only 2.9, which reduces classic squeeze pressure. Options positioning is in a positive gamma regime, which can damp volatility mechanically, but after a 137% month and a price near the high, positioning looks more supportive of trend persistence than fundamental validation.
Bull Case
- Management reiterated up to 10% FY26 revenue growth and cut both GAAP opex ex litigation and cash cost guidance by $0.2B, to $4.7B and $4.0B respectively.
- Balance sheet remains a real cushion, with $6.9B cash and investments at Q2 and expected $4.7B-$5.2B year-end cash and investments even after a $950M litigation payment in Q3.
- Commercial execution in COVID improved with mNEXSPIKE capturing 24% of the U.S. retail COVID market in its first season.
- Recent earnings execution has been better than feared, with 8 straight EPS beats, including +72.7%, +28.8%, and +23.6% versus consensus in the last seven reported quarters.
Bear Case
- The core business is still shrinking, with FY2025 revenue of $1.9B, down 37.5% YoY, and management still assumes a decline in U.S. COVID vaccination rates in FY26.
- The market is paying a premium multiple for a money-losing company, at 27.38x sales and 9.02x book, while peers average just 7.7x sales and profitable biotech peers trade at 15.84x to 31.95x earnings.
- Pipeline execution is mixed: mRNA-1403 norovirus Phase III did not meet the statistical criteria for early success at interim and now requires an added cohort.
- Operating leverage is still poor, with Q2 2026 EBITDA margin of -485.5% and FY26 cost of sales still guided at $1.7B against only up to 10% annual revenue growth.
Valuation & Price Target
Engine price target $107.73 (-38.3% vs current), Low confidence.
- P/S Multiple: $47.92 (28% weight)
- Quality-adjusted: $190.1 (20% weight)
This call aligns with the quant baseline of SELL, and the low conviction is appropriate because the recent cancer-vaccine narrative could keep the stock elevated longer than fundamentals justify. The engine target of $107.73 is reasonable because the stock trades at 27.38x sales on $1.9B FY2025 revenue, versus 7.7x for peers, while profitability is still deeply negative at -118.0% operating margin and management is guiding only up to 10% FY26 revenue growth. The quality-adjusted component at $190.1 captures the balance sheet and platform value, but the lower blended target fits better because late-stage execution is mixed and peer dispersion is wide at 5.1x, which weakens multiple-based upside arguments. Sell-side consensus sits at Hold with 3 buy / 8 hold / 3 sell, but that is low-signal context and not enough to offset the disconnect between price and current earnings power.
Risk Assessment
Risk score 50/100 (Moderate). The biggest risk to a bearish call is that oncology optimism overwhelms near-term fundamentals, especially after the stock already rose 159.39% in 3 months and options positioning is in a positive gamma regime.
The Bottom Line
MRNA rates a SELL at Low conviction. The business has real scientific assets and enough cash to keep building them, but the stock already reflects a much better commercial outcome than current numbers support. At 27.38x sales with -118.0% operating margin and only up to 10% FY26 revenue growth guided, the burden of proof is on the bull case. A more positive stance would require evidence that new products can lift revenue materially above the current trajectory, or that oncology progress turns into visible earnings power rather than momentum-driven sentiment.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr